Mounting evidence suggests that opiate addiction and stress are associated with impaired cell-mediated immunity. We tested the hypothesis that morphine and the endogenous opioid fl-endorphin (f-END), a pituitary peptide released in increased concentrations during stress, can suppress the production of the key macrophage-activating lymphokine interferon-v (IFN-'y) by cultured human peripheral blood mononuclear cells (PBMNC). Using a radioimmunoassay to measure IFN-'y, we found that exposure of PBMNC to biologically relevant concentrations of both opioids significantly inhibited IFN-'y generation by cells stimulated with coucanavalin A and varicella zoster virus. Studies of the mechanism of suppression revealed (a) a classical opioid receptor is involved (suppression was antagonized by naloxone and was specific for the NH2 terminus of f-END), (b) monocytes are the primary target cell for opioids (monocyte-depleted lymphocyte preparations showed little suppression), and (c) reactive oxygen intermediates (ROI) and prostaglandin E2 are important mediators (scavengers of ROI and indomethacin eliminated the suppression). Based on these findings we suggest that opioid-triggered release of inhibitory monocyte metabolites may play a role in the immunodeficiency associated with narcotic addiction and stress.
Introduction
During the past several years, the immunodulatory effects of opiates and endogenous opioid peptides have received considerable attention (1) (2) (3) (4) . Evidence is accumulating from both in vivo and in vitro sources that points to important interactions between opiates and T lymphocytes (5) (6) (7) (8) (9) (10) (11) (12) and mononuclear phagocytes (13) (14) (15) . Of highly related interest have been studies with fl-endorphin (,8-END)' (15) (16) (17) (18) (19) . From these latter studies has evolved the concept that B-END as well as other neuropeptides function as communication signals between the nervous system and the immune system (3, 20, 21) . Since ,8-END is released in increased quantities from the anterior pituitary during stress, the possibility exists that this peptide hormone is partly responsible for the suppressed cell-mediated immunity that accompanies stress (22) (23) (24) (25) .
Effective cell-mediated immunity has been known for some time to be dependent upon activation ofmacrophages by T lymphocytes, and interferon-y (IFN-'y) now has been identified as the principal T cell lymphokine responsible for enhancement of macrophage microbicidal (26, 27) and tumoricidal (28, 29) activity. In addition to its macrophage-activating properties, IFN-,y, which is produced by activated T lymphocytes and natural killer cells (30) , has multiple other functions in host defense (31) (32) (33) .
Recently, Johnson et al. (34) have demonstrated that corticotropin (ACTH), a proopiomelanocortin (POMC)-derived peptide that is co-secreted with fl-END, markedly suppresses INF-y production in mouse spleen cell cultures. In the present study, we investigated the effects of f-END and morphine on IFN-1Y production by cultured human peripheral blood mononuclear cells (PBMNC). We found that both of these opioids profoundly inhibit IFN-y generation in this cell system. The mechanism ofsuppression appears to involve a classical opioid receptor in which monocytes serve as the primary target cell with depressed lymphocyte activation and INF-y production occurring as a consequence of the release of inhibitory monocyte metabolites.
Methods

Cell preparations
PBMNC. Heparinized venous blood was obtained from healthy volunteers with a mean age of 36 yr (range 24-43 yr) who were not taking any medications. PBMNC were isolated by adding dextran (3 ml dextran to 10 ml blood) and layering on lymphocyte separation medium (Litton Bionetics, Inc., Kensington, MD). After centrifugation, the mononuclear cell layer was washed twice and resuspended in Hank's balanced salt solution containing 0.1% gelatin (GHBSS) to yield a final concentration of 2 X 106 PBMNC/ml GHBSS. Cytocentrifuge preparations were examined, and monocytes and lymphocytes were enumerated. In addition to morphologic features, monocytes were identified by staining for nonspecific esterase (35) . Using these techniques, PBMNC suspensions were found to contain from 15 to 38% monocytes and from 62 to 85% lymphocytes.
Purified mononuclear cell preparations. Monocytes were isolated from heparinized venous blood using microexudate-coated tissue culture flasks (36, 37) ; final cell suspensions contained > 95% monocytes. Monocyte-depleted lymphocyte preparations were recovered from the nonadherent cells by sequential passage on microexudate-coated tissue culture flasks for 45 min followed by incubation on uncoated polystyrene tissue culture flasks (Corning Glass Works, Corning, NY) for 45 cytes (range 95-98% lymphocytes) and 3% monocytes (range 2-5% monocytes).
Cell viability. All cell preparations contained > 95% viable cells as assessed by trypan blue exclusion criteria. Exposure of cells to opioids during cell culture, both in the presence and absence of stimuli of INF-y production, did not affect cell viability when compared with cultured control cells.
Cell culture medium. For all assays, PBMNC and purified cell preparations were incubated in a culture medium consisting of RPMI 1640 (Sigma Chemical Co., St. Louis, MO) with 20% defined bovine serum (HyClone Laboratories, Sterile Systems, Inc., Logan, UT) containing 100 U penicillin/ml, 100 pg streptomycin/ml (Gibco, Grand Island, NY), and 2 mM L-glutamine (KC Biological, Inc., Lenexa, KA).
Opioids and related materials
Morphine sulphate and naloxone were kindly provided by the National Institute on Drug Abuse. Human sources of ,-END1,31, 
IFN-,y production and measurements
For each experiment, 100 pI volumes of cell suspension (2 X 105 cells in GHBSS) were pipetted in replicates of five or six into 96-well flatbottom microtiter plates (Flow Laboratories, Inc., McLean, VA), centrifuged, and resuspended in 100 p1 culture medium alone (control) or culture medium containing opioids or ACTH at indicated final concentrations. In experiments with naloxone, cells were preincubated with this antagonist for 30 min at indicated concentrations before adding opioids. After the stated period of exposure to opioids and ACTH, 10 1 culture medium alone (unstimulated cells), culture medium containing an optimal-stimulating 10 pg/ml dose ofconcanavalin A (con A; Sigma Chemical Co.), or a 1:50 dilution ofvaricella zoster virus (VZV; Whitaker M. A. Bioproducts, Walkersville, MD) (stimulated cells) was added, and plates were then incubated for 72 h (con A experiments) or 6 d (VZV experiments) at 37°C in a 5% CO2 incubator. After centrifugation, supernatant fluids were collected.
To measure the secretion of IFN-y into the supernatant fluids, radioimmunoassay (38) kits (Centocor Corp., Malvern, PA) were used with minor modifications of a previously described method (39 The effect of prostaglandin E2 (PGE2) on IFN--y production was tested by adding PGE2 (Sigma Chemical Co.) at the indicated final concentrations to PBMNC cultures before adding con A, and determining IFN-'y production after 72 h incubation.
To determine whether #-END mediated its effect through stimulation of prostaglandin metabolism, PBMNC (2 X 
Results
Opioid suppression of con A-stimulated cells. The effect of opioids on con A-stimulated IFN-,y production was evaluated initially using concentrations of morphine and #-END that were considered to fall within pharmacologically (10-1o-10-6 M) and physiologically (10-100-10-M) relevant ranges, respectively ( Fig. 1 ). While con A-stimulated control cells yielded close to 100 U IFN-y, PBMNC that were exposed to opioids at these concentrations generated < 50 U IFN-'y, a difference that was statistically significant for morphine at all concentrations and for (3-END at 10-12_0-10 M. When cells were exposed to morphine and d-END at 10-18_10-12 M, significant inhibition of IFN-y production was observed only at 1012 M (data not shown), and at this concentration morphine and (3-END had similar inhibitory potencies of 51 and 49%, respectively.
In the preceding experiments, PBMNC were incubated with morphine and (3-END for 3 h before adding con A. Using 10-8 M morphine and 10-12 M (3-END, we found that maximal suppression of IFN-y was achieved within 3 h, i.e., preincubation of PBMNC with opioids for 1 h before adding con A resulted in only 25% suppression of IFN-y release, whereas preincubation for 24 h did not afford any greater suppression than that observed when cells were exposed to opioids for only 3 h. Also, removal of the opioids by washing after the 3-h preincubation eliminated their suppressive effect, although removal after 24 h preincubation resulted in -20% suppression (data not shown). Thus, for all subsequent experiments, PBMNC were exposed to opioids for 3 h before adding con A, and the opioids were left in the cell cultures throughout the 72-h incubation.
Unstimulated control cells produced small amounts of IFN-y (Fig. 1) . In subsequent experiments, the value for unstimulated control cells, which averaged 2 U IFN-y, was substracted from those obtained with stimulated cells. Incubation of PBMNC with morphine (10-10l10-6 M) and (3-END (10-14_10-'0 M) alone for 72 h did not yield IFN-y levels that were any higher than those observed with unstimulated control cells (data not shown).
Since other investigators have demonstrated that the POMC-derived peptide ACTH is capable of inhibiting IFN-'y production (34), we next compared the suppressive activity of (-END to that of ACTH. PBMNC exposed to (3-END and ACTH for 3 h at 10-!2 M concentrations before stimulation with 10 ,g con A for 72 h secreted only 24±15 U and 18±4 U IFN-y, respectively, as compared with 1 15±5 U IFN-'y generated by control cells (P < 0.05, n = 3). Thus, at a concentration of 10"2 M, the suppressive activity of these two anterior pituitary peptides appears to be relatively similar. At concentrations ranging from 10-18 to 10-14 M, neither peptide gave significant inhibition (data not shown). Involvement of a classical opioid receptor in suppression. To determine whether opioids mediate their suppressive effect on PBMNC IFN-'y production via a classical opioid receptor mechanism, we first studied the influence ofthe opioid antagonist naloxone in this system. Whereas naloxone itself did not significantly inhibit IFN-'y production, it completely abrogated the suppressive activities of morphine and (3-END at equimolar concentrations (Fig. 2) .
Responses to endorphins that involve classical opioid receptors are mediated through the NH2 terminus of these peptides, and N-acetylation of (3-END markedly decreases its affinity for the opioid receptor rendering it inactive (41, 42) . When we compared the suppressive activity ofNAC-,B-END to (3-END at concentrations from l0-'4 to 10-' M, significant suppression of PBMNC IFN-'y generation was observed only with (-END (Fig. 3) . The effect of altering the carboxy terminus of(3-END was assessed by studying the suppressive activity of (3-END1.27, a manipulation that did not change its inhibitory potency (Fig. 3) . Taken together with the experiments demonstrating antagonism by naloxone, these findings indicate that a classical opioid receptor is involved in opioid-mediated suppression of PBMNC IFN-ny production.
To control for proteolytic degradation of (3-END and to assess whether the N-terminal five amino acid sequence of (13) . Since monocytes have been shown to play a primary role in modulating various lymphocyte activities, we investigated their contribution to opioid-mediated suppression of PBMNC IFN-y production. Monocytes were first removed from PBMNC preparations by adherence techniques yielding cell populations that contained > 95% lymphocytes. When these relatively pure lymphocyte preparations were exposed to #-END before adding con A, the suppression of IFN--y release was less pronounced than that observed with simultaneously studied PBMNC preparations that contained an average of 28% monocytes (Fig. 4) . This finding suggested that monocytes play a role in the suppression of PBMNC IFN-y release. Since equivalent numbers ofcells (2 X 10i lymphocytes or 2 X I0 PBMNC per well) were used in this experiment, the greater IFN-y production by control-purified lymphocytes as compared with control PBMNC may reflect the removal of monocytes that are normally somewhat inhibitory, or it could simply be due to the presence ofa greater number of lymphocytes in the purified lymphocyte preparations.
To further investigate the involvement of monocytes in opioid-mediated suppression of IFN-'y production, relatively pure populations of monocytes and of lymphocytes were incubated in the absence and presence of #-END for 72 h. The supernatants were then harvested from these cells and added to purified lymphocyte preparations. After 72 h incubation with con A, IFN-y release from these lymphocyte preparations was 120 T Figure 4 . (47, 48) , or both of these factors (49) are capable of inhibiting other lymphocyte activities, we studied their involvement in opioid-mediated suppression of IFN-'y production. When morphine and fl-END-exposed PBMNC were incubated in the presence of SOD or catalase, opioid-mediated suppression of IFN-,y production was abolished (Fig. 5) . Neither SOD nor catalase alone significantly altered IFN-y production by control PBMNC (data not shown). Similarly, the addition of0.5 uM indomethacin to the cell cultures completely blocked morphine and fl-END-mediated suppression, whereas indomethacin alone Opioid Suppression ofInterferon-y 827 had little effect on IFN-'y production by control PBMNC (Fig.   6 ). Moreover, administration of indomethacin to volunteers for 2-3 d before isolating their PBMNC, resulted in inhibition of the suppressive activities of morphine and U-END with these cells in vitro (Fig. 7) . Next, the suppressive capacity of one of the prostaglandin metabolites considered likely to be involved in this system, namely PGE2, was studied. When PGE2 was added to PBMNC, significant suppression of con A-stimulated IFN-i production was observed at a concentration of 10-8 M (Table  III) . Finally, to test whether U-END is capable ofmediating the release of PGE2 from PBMNC, cells were exposed to 10-12 M ,8-END for 3 h (the period oftime that had been determined to be necessary for optimal IFN-y suppression), and PGE2 was measured in the culture supernatants. Supernatants from In summation, the results ofthese experiments suggest that opioids trigger the release of ROI intermediates and PGE2 from monocytes and that each of these metabolites in turn is inhibition of IFN-'y production was observed with both morphine and ,-END (Fig. 8 ). These findings indicate that opioids are capable of suppressing PBMNC IFN-,y production in response to a specific antigen (VZV) but that a relatively prolonged interval of opioid exposure is required before the suppressive effect becomes manifest.
Discussion
In this study, we have demonstrated that morphine and S-END, at remarkably low concentrations, are capable of suppressing IFN-y production by PBMNC stimulated by both a nonspecific T cell mitogen (con A) and a specific antigen (VZV). Our data suggest that monocytes are the primary target cell for opioids in this system and that morphine and ,8-END operate via a classical opioid receptor mechanism. Other investigators have shown that blood monocytes possess classical opiate receptors (13) , and activation of these receptors has been implicated in the inhibiton of the production of another lymphokine, T lymphocyte chemotactic factor (18) . Additional studies will be necessary to determine whether S-END binds to the same class of receptors on monocytes as does morphine, i.e., mu receptors, or if a separate class of receptors is involved, such as epsilon receptors, which have been described in other tissues (50, 51) . Other investigators have shown that :-END is rapidly internalized by human polymorphonuclear leukocytes (52) . Whether receptor-mediated internalization of U-END by monocytes also occurs and the importance of such a step in the sequence of events leading to suppression of IFN-'y production are at the present time unknown.
U-END has been shown to stimulate human peripheral blood lymphocyte natural killer cytolytic activity (53) (54) (55) (56) , and recent studies indicate that V-END augments interferon production by these cells (57) . IFN--y production by activated T lymphocytes is correlated with blastogenesis (58), and this response is regulated by the monokine interleukin 1 and the T cell growth factor interleukin 2 (59-61). The opioid-mediated suppression of PBMNC IFN-i generation that we observed in the present study appeared to be associated with depressed T lymphocyte-proliferative activity, and it is possible that reduced production of or responsiveness to one or more ofthese interleukins is a more proximate cause of suppressed IFN-'y secretion.
In keeping with the results of other investigators (47, 48, 62), our findings with indomethacin suggest that a product of monocyte prostaglandin metabolism plays an important role in suppression of T lymphocyte IFN--y generation. In the present study, S-END was found to trigger the release ofPGE2 from PBMNC. In contrast to the limited capacity of lymphocytes to produce this arachadonic acid metabolite, monocytes are known to be a rich source ofPGE2 (63) . PGE2 is recognized to be a potent inhibitor of many monocyte and lymphocyte functions (63, 64) , including IFN-y production (65), a finding corroborated in the present study. In a previous study, Goodwin et al. (66) found that physical stress was associated with depressed mitogen-induced lymphocyte proliferation which appeared to be linked to monocyte-derived PGE2. It is interesting to speculate that a stress-responsive peptide, such as S-END, may have triggered these monocytes to release PGE2. Since PGE2 appears to exert most of its physiologic effects through changes in intracellular cyclicAMP (63) , it is possible that cyclic nucleosides play an important role as second messengers in (i-END-mediated suppression of IFN--y production. The fact that scavengers of ROI also blocked opioid-mediated suppression of IFN-'y production is consistent with the view that these metabolites may contribute to prostaglandin metabolism (49) .
Although the biological significance of our findings is at present unknown, the most relevant paradigms approximated by this in vitro model may be those of opiate addiction and chronic stress since relatively prolonged periods of exposure to morphine and A-END were required to obtain maximal suppression of IFN-'y production. If this is the case, the defective Opioid Suppression ofInterferon-y 829 cell-mediated immunity associated with these disorders could in part be explained by monocyte-derived PGE2 occurring as a consequence of opioid stimulation of these cells. Given this scenario, the observation that oral administration of indomethacin blocked the suppressive activities of opioids may have clinical implications. Also, if opiate addiction and stress are shown to be cofactors in the pathogenesis of opportunistic infections in diseases such as the acquired immunodeficiency syndrome (67) , therapeutic strategies ultimately may be developed to counteract the immunosuppressive activities of the opioids involved under these conditions. Finally, recent studies indicate that splenic macrophages and lymphocytes express the POMC gene (68) (69) (70) , and it is possible that the 3-END that is produced by these cells may play an important role in the down-regulation of lymphocyte IFN-'y generation.
